Analytical Data
-
Gene name
psmA3
- Application
-
Alternative Names
/
-
Species
Staphylococcus aureus
-
Source
E. coli
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0C810
-
Expression Region
1-22aa
-
Molecular Weight
2.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSMA3, a significant component of the 26S proteasome, is involved in the ubiquitin-proteasome pathway, which plays a crucial role in protein degradation and regulation of various cellular processes. Its complex formation with other proteasomal subunits ensures the maintenance of protein homeostasis, as well as the modulation of key signaling pathways that govern cell cycle progression, apoptosis, and immune responses. Dysregulation of PSMA3 has been linked to several diseases, including cancer and neurodegenerative disorders, making it a target of interest for therapeutic interventions. Recent studies have focused on the structural and functional characterization of PSMA3, exploring its enzymatic activity and interaction with substrates and inhibitors. Recombinant PSMA3 proteins are being developed for both basic research and potential clinical applications, including the design of proteasome inhibitors and the elucidation of the mechanisms underlying proteasome-related pathologies. Understanding the role of PSMA3 at a molecular level is pivotal for the development of novel pharmacological strategies aimed at modulating proteasomal activity for therapeutic purposes.
